Today’s Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen
U.S. equities saw losses on Tuesday as continued weakness in oil prices pressured energy stocks lower. Crude oil dropped for the 12th consecutive session, its longest losing streak in three decades. The Dow Jones Industrial Average dropped 0.40 percent to close at 25,286.49, while the S&P 500 Index shed 0.15 percent to close at 2,722.18. The Nasdaq Composite Index closed almost flat at 7,200.88.
RDI Initiates Coverage on:
Amicus Therapeutics, Inc.
Amicus Therapeutics’ stock jumped 6.63% Tuesday, to close the day at $10.78. The stock recorded a trading volume of 2,634,226 shares, which was below its three months average volume of 2,780,992 shares. In the last year, Amicus Therapeutics’ shares have traded in a range of 10.08 – 17.62. The share price has gained 6.94% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $11.94 is below its 200-day moving average of $14.02. Shares of Amicus Therapeutics have fallen roughly 12.99 percent in the past month and are down 25.09 percent year-to-date.
Access RDI’s Amicus Therapeutics, Inc. Research Report at:
On Tuesday, shares of FibroGen recorded a trading volume of 618,151 shares, which was above the three months average volume of 532,233 shares. The stock ended the day 3.25% higher at $40.67. The share price has fallen 40.67% from its 52 week high with a 52 week trading range of 38.52 – 68.55. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $50.58 is below its 200-day moving average of $56.44. Shares of FibroGen have fallen roughly 18.32 percent in the past month and are down 14.2 percent year-to-date.
Access RDI’s FibroGen, Inc. Research Report at:
Our Actionable Research on Amicus Therapeutics, Inc. (NASDAQ:FOLD) and FibroGen, Inc. (NASDAQ:FGEN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.